Ben Tre Pharma (DBT) Overhauls Board, Appoints Nam A Bank Chairman's Daughter

Overview

Ben Tre Pharmaceutical (DBT) has undergone a significant leadership change following an extraordinary shareholder meeting. The company replaced five board members and appointed a new chairman and deputy general director, including Tran Ngo Minh Anh, the daughter of Nam A Bank’s chairman. This move signals a strategic shift for the pharmaceutical firm listed on HOSE.

Key Facts

• DBT held an extraordinary shareholder meeting, removing five board members: Nguyen Khac Hanh, Pham Thu Trieu, Nguyen Thai Duong, Nguyen Thanh Tung, and Tran Nguyen Gia Bao.
• Five new board members were elected: Phan Nhat Thanh, Tran Ngo Minh Anh, Le Thi Hoang Han, Pham Hong Ha, and Tran Dinh Van.
• Tran Dinh Van was appointed Chairman of the Board and legal representative; he has 33 years of state employment and currently chairs Hue International General Hospital and Phu Yen Pharmaceutical Import-Export.
• Nguyen Khac Hanh was appointed General Director and legal representative.
• Tran Ngo Minh Anh, born 2002, was appointed Deputy General Director; she holds a finance degree from Central Florida University and worked at New Omni Bank in California (2024-2026). She currently owns no DBT shares.
• In Q2 2026, DBT reported revenue of VND 228 billion (down 6.4% YoY) and net profit of VND 9.8 billion (up 17% YoY).
• For H1 2026, net revenue reached VND 418 billion (+3% YoY) and net profit VND 25 billion (+140% YoY), driven by a VND 15 billion increase in financial income.
• Total assets fell 11% to VND 108 billion from the start of the year; cash dropped 50% to VND 10 billion.

What Happened

At the extraordinary shareholder meeting, DBT shareholders voted to dismiss five existing board members and elect five new ones, effectively resetting the board. The new board then held its first session, electing Tran Dinh Van as Chairman and legal representative, and appointing Nguyen Khac Hanh as General Director and Tran Ngo Minh Anh as Deputy General Director.

Tran Ngo Minh Anh, the daughter of Nam A Bank’s Chairman Tran Ngo Phuc Vu, brings international finance experience from her role at New Omni Bank in California. The company’s disclosure notes she holds no DBT shares. The leadership change follows a period of financial contraction, with total assets down 11% in the first half of 2026, though net profit surged 140% due to financial income gains.

Market Context

DBT, listed on HOSE, closed at VND 13,000 on August 3, 2026. The stock has been under pressure amid the company’s shrinking balance sheet and modest revenue growth. The pharmaceutical sector in Vietnam remains competitive, with smaller players like DBT facing challenges from larger peers. The leadership overhaul may signal a strategic pivot, but the market will watch for concrete operational improvements.

Strategic Significance

The appointment of Tran Ngo Minh Anh, with her international banking background, could bring fresh perspectives on financial management and potential synergies with Nam A Bank’s network. The new chairman, Tran Dinh Van, has extensive state and healthcare sector experience, which may help DBT navigate regulatory and operational complexities. However, the lack of share ownership by the new deputy CEO raises questions about long-term commitment. Investors should assess whether this leadership change translates into improved profitability and asset efficiency.

What to Watch

• Q3 2026 earnings release: Will revenue growth accelerate and asset contraction reverse?
• Any strategic partnerships or M&A activity involving DBT, possibly leveraging Nam A Bank connections.
• Changes in dividend policy or capital allocation under the new board.
• Regulatory approvals or product launches that could boost DBT’s market position.
• Further board or management changes that might indicate ongoing instability.